4//SEC Filing
Regado Biosciences Inc 4
Accession 0001140361-13-034588
CIK 0001311596operating
Filed
Aug 28, 8:00 PM ET
Accepted
Aug 29, 4:37 PM ET
Size
27.1 KB
Accession
0001140361-13-034588
Insider Transaction Report
Form 4
Wisniewski Raphael
Director10% Owner
Transactions
- Conversion
Common Stock, par value $0.001 per share
2013-08-27+1,021,930→ 1,021,930 total(indirect: See Footnote 4) - Award
Stock Option (right to buy)
2023-08-27+17,964→ 17,964 totalExercise: $4.00Exp: 2013-08-27→ Common Stock, par value $0.001 per share (17,964 underlying) - Conversion
Series D Preferred Stock
2013-08-27−17,066,243→ 0 total(indirect: See Footnote 4)→ Common Stock, par value $0.001 per share (1,021,930 underlying) - Conversion
Series E Preferred Stock
2013-08-27−2,832,872→ 0 total(indirect: See Footnote 4)→ Common Stock, par value $0.001 per share (169,633 underlying) - Purchase
Common Stock, par value $0.001 per share
2013-08-27$4.00/sh+1,215,708$4,862,832→ 2,407,271 total(indirect: See Footnote 4) - Conversion
Common Stock, par value $0.001 per share
2013-08-27+169,633→ 1,191,563 total(indirect: See Footnote 4)
Footnotes (4)
- [F1]100% of the shares underlying the option will vest on the one-year anniversary of the date of grant.
- [F2]The shares of Series D Preferred Stock had no expiration date and automatically converted upon the consummation of the initial public offering of Regado Biosciences, Inc. (the "Company") at a conversion ratio of 1 share of Series D Preferred Stock to 0.05988024 shares of common stock, for no additional consideration.
- [F3]The shares of Series E Preferred Stock had no expiration date and automatically converted upon the consummation of the Company's initial public offering at a conversion ratio of 1 share of Series E Preferred Stock to 0.05988024 shares of common stock, for no additional consideration.
- [F4]The reportable securities are directly held by BioDiscovery 3, FCPR ("BioDiscovery") and indirectly held by Edmond de Rothschild Investment Partners ("Edmond de Rothschild"), BioDiscovery's management company. The Reporting Person is a partner at Edmond de Rothschild. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, and this report is not an admission that he is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
Documents
Issuer
Regado Biosciences Inc
CIK 0001311596
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001311596
Filing Metadata
- Form type
- 4
- Filed
- Aug 28, 8:00 PM ET
- Accepted
- Aug 29, 4:37 PM ET
- Size
- 27.1 KB